Xeris Biopharma (NASDAQ:XERS) Stock Price Up 5.4% – Time to Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock price rose 5.4% during mid-day trading on Thursday . The stock traded as high as $5.64 and last traded at $5.5850. Approximately 765,476 shares were traded during trading, a decline of 62% from the average daily volume of 2,008,487 shares. The stock had previously closed at $5.30.

Wall Street Analyst Weigh In

XERS has been the subject of several analyst reports. Barclays assumed coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target for the company. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Xeris Biopharma Stock Down 3.1%

The company has a 50-day moving average of $6.49 and a two-hundred day moving average of $7.35. The company has a market capitalization of $931.12 million, a P/E ratio of -539.46 and a beta of 0.61. The company has a quick ratio of 1.57, a current ratio of 2.19 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The company had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. On average, research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $6.25, for a total transaction of $104,168.75. Following the completion of the transaction, the insider directly owned 1,226,507 shares in the company, valued at $7,665,668.75. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the transaction, the insider directly owned 2,705,346 shares of the company’s stock, valued at $19,153,849.68. This trade represents a 0.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 89,908 shares of company stock valued at $648,515. Insiders own 6.47% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Calamos Advisors LLC bought a new stake in shares of Xeris Biopharma in the 3rd quarter worth $1,116,000. Voya Investment Management LLC lifted its holdings in shares of Xeris Biopharma by 866.6% during the third quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock valued at $3,257,000 after purchasing an additional 358,689 shares in the last quarter. Divisadero Street Capital Management LP bought a new position in shares of Xeris Biopharma during the third quarter valued at $3,308,000. Squarepoint Ops LLC boosted its position in shares of Xeris Biopharma by 1,679.1% during the second quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock valued at $1,329,000 after buying an additional 268,572 shares during the last quarter. Finally, Granahan Investment Management LLC bought a new stake in Xeris Biopharma in the 3rd quarter worth about $2,850,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.